These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 7732557

  • 21. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 22. Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration.
    Jankauskiene A, Druskis V, Laurinavicius A.
    Clin Nephrol; 2001 Dec 15; 56(6):S27-9. PubMed ID: 11770808
    [Abstract] [Full Text] [Related]

  • 23. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A, Grant DR, Kneteman NM, Tchervenkov JI, Levy GA, Tan A, Hendricks L.
    Ann Chir; 1998 Dec 15; 52(8):716-21. PubMed ID: 9846420
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
    Schulz T, Kapischke M, Busing M.
    Transplant Proc; 2005 May 15; 37(4):1815-7. PubMed ID: 15919475
    [Abstract] [Full Text] [Related]

  • 26. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E.
    Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M, Tscheliessnigg K.
    Transpl Immunol; 2006 Jun 27; 16(1):46-51. PubMed ID: 16701176
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P, Baron C, Fruchaud G, Hemery F, Desvaux D, Buisson C, Chopin D, Dahmane D, Remy P, Pastural M, Abbou C, Weil B, Lang P.
    Transpl Int; 2002 Nov 27; 15(11):550-5. PubMed ID: 12461659
    [Abstract] [Full Text] [Related]

  • 33. Serum cyclosporine kinetic profile. Failure to correlate with nephrotoxicity or rejection episodes following sequential immunotherapy for renal transplantation.
    Sommer BG, Sing DE, Henry ML, Ferguson RM, Orosz CG.
    Transplantation; 1988 Jan 27; 45(1):86-90. PubMed ID: 3276069
    [Abstract] [Full Text] [Related]

  • 34. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
    Wiesner RH, Porayko MK, Wahlstrom HE, Gores GJ, Kamath PS, Hay JE, Krom RA.
    Transplant Proc; 1993 Apr 27; 25(2):1791-3. PubMed ID: 7682352
    [No Abstract] [Full Text] [Related]

  • 35. Effects of cyclosporine, azathioprine, and steroids on the renal transplant, on the cytologic patterns of intragraft inflammation, and on concomitant rejection-associated changes in recipient blood.
    Häyry P, von Willebrand E, Ahonen J, Eklund B, Salmela K, Höckerstedt K, Pettersson E, Koskimies S.
    Transplant Proc; 1988 Apr 27; 20(2 Suppl 2):153-62. PubMed ID: 3284065
    [Abstract] [Full Text] [Related]

  • 36. Definition, diagnosis, and management of rejection in the second to sixth months posttransplant--an overview.
    Matas AJ, Tellis VA, Quinn T, Soberman R, Veith FJ.
    Transplant Proc; 1986 Apr 27; 18(2 Suppl 1):141-50. PubMed ID: 3515682
    [Abstract] [Full Text] [Related]

  • 37. Immunosuppression by combined use of cyclosporine and resveratrol in a rat liver transplantation model.
    Wu SL, Pan CE, Yu L, Meng KW.
    Transplant Proc; 2005 Jun 27; 37(5):2354-9. PubMed ID: 15964415
    [Abstract] [Full Text] [Related]

  • 38. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features.
    Freese DK, Snover DC, Sharp HL, Gross CR, Savick SK, Payne WD.
    Hepatology; 1991 May 27; 13(5):882-91. PubMed ID: 2029992
    [Abstract] [Full Text] [Related]

  • 39. Risk factors for the development of chronic cyclosporine-nephrotoxicity.
    Mihatsch MJ, Steiner K, Abeywickrama KH, Landmann J, Thiel G.
    Clin Nephrol; 1988 Apr 27; 29(4):165-75. PubMed ID: 3284669
    [Abstract] [Full Text] [Related]

  • 40. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial.
    Perico N, Ruggenenti P, Gotti E, Gaspari F, Cattaneo D, Valente U, Salvadori M, Segoloni G, Donati D, Sandrini S, Ganeva M, Dimitrov BD, Remuzzi G, MY.S.S. Study Investigators.
    Kidney Int; 2004 Mar 27; 65(3):1084-90. PubMed ID: 14871429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.